
Last updated: 2026-09-06 13:29:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Theravance Biopharma, Inc. (TBPH) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $17.09, with a market capitalisation of $886.25M and a P/E ratio of 16.48. Over the past 52 weeks, its price has ranged from $13.08 to $21.03. This page covers its latest market performance, valuation, price trends and company information.
$886.25M | |
$17.26 | |
$43.44 | |
$6.10 | |
$17.08 | |
132.95K | |
-- | |
16.48 | |
$21.03 | |
$13.08 | |
-- | |
-- |
Theravance Biopharma, Inc. (TBPH) last closed at $17.08 as of 2026-09-04 19:59:57, unchanged from the previous close of $17.08.
During the latest regular trading session, TBPH traded between $6.10 and $43.44, with a volume of 132.95K shares. The closing price was near the lower end and near the middle of its 52-week range.
Over the past seven days, Theravance Biopharma, Inc. (TBPH) moved from $17.03 to $17.09, representing a gain of 0.32% ($0.05).
The stock traded between $17.08 and $17.26 during the period. The latest price is near the lower end of the 7-day range, indicating range-bound.
The average daily volume was 455.08 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 50.4%
TBPH is currently trading at $17.09, placing it 50.4% of the way from its 52-week low of $13.08 to its 52-week high of $21.03. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 90 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Theravance Biopharma, Inc. (TBPH) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.